Hanmi Pharmaceutical's Immune-Oncology Innovative Drug Selected for National New Drug Development Project Support

Exterior view of Hanmi Pharmaceutical Research Center. [Photo by Hanmi Pharmaceutical]

[Asia Economy Reporter Lee Gwan-joo] Hanmi Pharmaceutical announced on the 8th that its immuno-oncology innovative drug under development, 'LAPS IL-2 analog,' has been selected as a recipient of the National New Drug Development Project support.

'LAPS IL-2 analog' is an immuno-oncology innovative drug developed by applying Hanmi Pharmaceutical's proprietary platform technology 'LAPSCOVERY,' which extends the efficacy duration of biopharmaceuticals, maximizing both durability and safety. It is a long-acting formulation that can be administered subcutaneously once per cancer treatment cycle, and it maximizes anticancer efficacy based on differentiated receptor binding affinity compared to existing IL-2 formulations.

A Hanmi Pharmaceutical official stated, "The LAPS IL-2 analog, with its maximized antitumor efficacy, is expected to significantly enhance therapeutic effects not only as a monotherapy but also by increasing immune response when combined with immune checkpoint inhibitors. Encouraged by the selection for this national support project, we will rapidly proceed with subsequent development toward final commercialization."

Including this, Hanmi Pharmaceutical now has a total of three innovative drugs selected for the National New Drug Development Project. Following the selection in September last year of the innovative drug for congenital hyperinsulinemia treatment, 'LAPS Glucagon analog (HM15136),' in November, 'HM97662,' a new targeted anticancer innovative drug for refractory malignant hematologic cancers and solid tumors, was also selected as a support recipient.

This content was produced with the assistance of AI translation services.